AV Daclatasvir
Aus coViki
(Unterschied zwischen Versionen)
(Die Seite wurde neu angelegt: „{{up|PHA antivirals by mechanism}} {{tp|p=32812025|t=2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospital…“) |
K |
||
| Zeile 1: | Zeile 1: | ||
{{up|PHA antivirals by mechanism}} | {{up|PHA antivirals by mechanism}} | ||
| + | {{qt|AV Sofosbuvir}} | ||
{{tp|p=32812025|t=2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.|pdf=|usr=018}} | {{tp|p=32812025|t=2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.|pdf=|usr=018}} | ||
{{tp|p=32812039|t=2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.|pdf=|usr=018}} | {{tp|p=32812039|t=2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.|pdf=|usr=018}} | ||
{{tp|p=32812051|t=2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.|pdf=|usr=018}} | {{tp|p=32812051|t=2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.|pdf=|usr=018}} | ||
{{tp|p=33063117|t=2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.|pdf=|usr=020}} | {{tp|p=33063117|t=2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.|pdf=|usr=020}} | ||
Aktuelle Version vom 11. April 2021, 16:21 Uhr
| PHA antivirals by mechanism |
| AV Sofosbuvir |
32812025 2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
32812039 2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
32812051 2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
33063117 2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
